| __timestamp | Gilead Sciences, Inc. | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 165772000 |
| Thursday, January 1, 2015 | 3426000000 | 196614000 |
| Friday, January 1, 2016 | 3398000000 | 303251000 |
| Sunday, January 1, 2017 | 3878000000 | 366406000 |
| Monday, January 1, 2018 | 4056000000 | 434407000 |
| Tuesday, January 1, 2019 | 4381000000 | 468711000 |
| Wednesday, January 1, 2020 | 5151000000 | 516922000 |
| Friday, January 1, 2021 | 5246000000 | 739560000 |
| Saturday, January 1, 2022 | 5673000000 | 1002140000 |
| Sunday, January 1, 2023 | 6090000000 | 1161300000 |
| Monday, January 1, 2024 | 6091000000 | 1242157000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Gilead Sciences, Inc. and Incyte Corporation have demonstrated contrasting strategies in this area. From 2014 to 2023, Gilead's SG&A expenses surged by over 100%, peaking at $6.09 billion in 2023. In contrast, Incyte's expenses grew at a more modest pace, increasing by approximately 600% to reach $1.16 billion in the same year.
While Gilead's larger scale might justify its higher expenses, Incyte's leaner approach could indicate a more efficient cost management strategy. This divergence highlights the different paths companies can take in optimizing operational costs, with Gilead focusing on expansive growth and Incyte prioritizing cost efficiency. As the biotech industry evolves, these strategies will continue to shape the financial landscapes of these two giants.
Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated
Gilead Sciences, Inc. vs Alnylam Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Regeneron Pharmaceuticals, Inc.
Gilead Sciences, Inc. vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and CRISPR Therapeutics AG
Comparing SG&A Expenses: Gilead Sciences, Inc. vs Galapagos NV Trends and Insights
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Incyte Corporation
BeiGene, Ltd. or Incyte Corporation: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Incyte Corporation and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Incyte Corporation and Corcept Therapeutics Incorporated